Humana AB (publ), together with its subsidiaries, provides individual and family care services for children, adolescents, and adults in Sweden, Finland, Norway, and Denmark. More Details
Very undervalued with moderate growth potential.
Share Price & News
How has Humana's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HUM is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HUM's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: HUM underperformed the Swedish Healthcare industry which returned 20.9% over the past year.
Return vs Market: HUM underperformed the Swedish Market which returned 15.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Humana's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAt kr62.00, Is Humana AB (publ) (STO:HUM) Worth Looking At Closely?
1 month ago | Simply Wall StIs Humana (STO:HUM) Using Too Much Debt?
1 month ago | Simply Wall StAre Strong Financial Prospects The Force That Is Driving The Momentum In Humana AB (publ)'s STO:HUM) Stock?
Is Humana undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HUM (SEK59.9) is trading below our estimate of fair value (SEK118.39)
Significantly Below Fair Value: HUM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HUM is good value based on its PE Ratio (13.8x) compared to the SE Healthcare industry average (22.5x).
PE vs Market: HUM is good value based on its PE Ratio (13.8x) compared to the Swedish market (23.7x).
Price to Earnings Growth Ratio
PEG Ratio: HUM is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: HUM is good value based on its PB Ratio (1.3x) compared to the SE Healthcare industry average (1.5x).
How is Humana forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HUM's forecast earnings growth (14.9% per year) is above the savings rate (0.4%).
Earnings vs Market: HUM's earnings (14.9% per year) are forecast to grow faster than the Swedish market (11% per year).
High Growth Earnings: HUM's earnings are forecast to grow, but not significantly.
Revenue vs Market: HUM's revenue (4.1% per year) is forecast to grow faster than the Swedish market (3.2% per year).
High Growth Revenue: HUM's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HUM's Return on Equity is forecast to be low in 3 years time (10.8%).
How has Humana performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HUM has high quality earnings.
Growing Profit Margin: HUM's current net profit margins (3%) are lower than last year (3.1%).
Past Earnings Growth Analysis
Earnings Trend: HUM's earnings have grown significantly by 22.6% per year over the past 5 years.
Accelerating Growth: HUM's earnings growth over the past year (3.8%) is below its 5-year average (22.6% per year).
Earnings vs Industry: HUM earnings growth over the past year (3.8%) exceeded the Healthcare industry -11.1%.
Return on Equity
High ROE: HUM's Return on Equity (9.2%) is considered low.
How is Humana's financial position?
Financial Position Analysis
Short Term Liabilities: HUM's short term assets (SEK2.0B) do not cover its short term liabilities (SEK2.1B).
Long Term Liabilities: HUM's short term assets (SEK2.0B) do not cover its long term liabilities (SEK3.8B).
Debt to Equity History and Analysis
Debt Level: HUM's debt to equity ratio (93.8%) is considered high.
Reducing Debt: HUM's debt to equity ratio has reduced from 152.5% to 93.8% over the past 5 years.
Debt Coverage: HUM's debt is well covered by operating cash flow (26.4%).
Interest Coverage: HUM's interest payments on its debt are not well covered by EBIT (2.7x coverage).
What is Humana current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HUM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HUM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HUM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HUM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: HUM is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HUM's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rasmus Nerman (42 yo)
Mr. Rasmus Nerman has been Chief Executive Officer and President of Humana AB since 2015. Mr. Nerman served as Deputy Chief Executive Officer of Humana. He served as Business Area Manager in Humana Individ...
CEO Compensation Analysis
Compensation vs Market: Rasmus's total compensation ($USD661.61K) is above average for companies of similar size in the Swedish market ($USD507.46K).
Compensation vs Earnings: Rasmus's compensation has been consistent with company performance over the past year.
|CEO & President||6yrs||kr5.50m||0.34% |
|Chief Financial Officer||0.33yr||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Director of Marketing & Communication||11yrs||no data||0.19% |
|Director of Human Resource||4yrs||no data||no data|
Experienced Management: HUM's management team is seasoned and experienced (5 years average tenure).
|Independent Director||1.67yrs||kr245.00k||no data|
|Independent Chairman of the Board||1.67yrs||kr408.00k||0.20% |
|Independent Director||0.67yr||no data||no data|
|Independent Director||4yrs||kr250.00k||0.020% |
|Independent Director||1.67yrs||kr181.00k||0.018% |
|Independent Director||4yrs||kr243.00k||0.0030% |
|Independent Director||0.67yr||no data||no data|
Experienced Board: HUM's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Humana AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Humana AB (publ)
- Ticker: HUM
- Exchange: OM
- Founded: 2001
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: kr3.039b
- Shares outstanding: 50.48m
- Website: https://www.humana.se
Number of Employees
- Humana AB (publ)
- Warfvinges vAeg 39
- 7th floor
- Stockholm County
- 112 51
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HUM||OM (OMX Nordic Exchange Stockholm)||Yes||Ordinary B Shares||SE||SEK||Mar 2016|
|47H||DB (Deutsche Boerse AG)||Yes||Ordinary B Shares||DE||EUR||Mar 2016|
|HUMS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary B Shares||GB||SEK||Mar 2016|
|0RF7||LSE (London Stock Exchange)||Yes||Ordinary B Shares||GB||SEK||Mar 2016|
Humana AB (publ), together with its subsidiaries, provides individual and family care services for children, adolescents, and adults in Sweden, Finland, Norway, and Denmark. The company operates through In...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/26 20:24|
|End of Day Share Price||2021/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.